Warfarin pharmacogenomics: Current best evidence

Journal of Thrombosis and Haemostasis

Volumn 13, Issue S1, 2015, Pages S266-S271

  Kimmel, S E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Drug therapy; Genetics; Pharmacogenetics; Randomized controlled trials as topic; Warfarin

Indexed keywords

ACENOCOUMAROL; CYTOCHROME P450 2C9; PHENPROCOUMON; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN; ANTICOAGULANT AGENT;

AFRICAN AMERICAN; ALGORITHM; ANALYTICAL VALIDITY; ANTICOAGULANT THERAPY; CLINICAL ALGORITHM; CLINICAL VALIDITY; CYP2C9 GENE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; GENETIC ALGORITHM; GENETIC BASED PRESCRIBING; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; PATIENT MONITORING; PERCENT TIME IN THERAPEUTIC RANGE; PHARMACOGENOMICS; PHARMACOLOGICAL PARAMETERS; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STUDY DESIGN; VALIDITY; VKORC1 GENE; BLOOD CLOTTING; BLOOD CLOTTING TEST; DOSE CALCULATION; DRUG EFFECTS; DRUG MONITORING; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; TREATMENT OUTCOME;

ALGORITHMS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; GENOTYPE; HUMANS; PHARMACOGENETICS; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; WARFARIN;

EID: 84931433310     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12978     Document Type: Review

References (19)

1. Ginsburg GS, Voora D. The long and winding road to warfarin pharmacogenetic testing. J Am Coll Cardiol 2010; 55: 2813-5.
2. Burke W, Laberge AM, Press N. Debating clinical utility. Public Health Genomics 2010; 13: 215-23.
3. Ashley EA, Hershberger RE, Caleshu C, Ellinor PT, Garcia JG, Herrington DM, Ho CY, Johnson JA, Kittner SJ, Macrae CA, Mudd-Martin G, Rader DJ, Roden DM, Scholes D, Sellke FW, Towbin JA, van Eyk J, Worrall BB. Genetics and cardiovascular disease: a policy statement from the American Heart Association. Circulation 2012; 126: 142-57.
4. Woodcock J, Lesko LJ. Pharmacogenetics-tailoring treatment for the outliers. N Engl J Med 2009; 360: 811-3.
5. Centers for Disease Control and Prevention (CDC). Genomic Testing. http://www.cdc.gov/genomics/gtesting/ACCE/index.htm. Accessed 2 February 2015.
6. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009; 11: 3-14.
7. Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med 2015; 25: 33-41.
8. Suarez-Kurtz G, Botton MR. Pharmacogenomics of warfarin in populations of African descent. Br J Clin Pharmacol 2013; 75: 334-46.
9. Epstein RS, Moyer TP, Aubert RE, O Kane DJ, Xia F, Verbrugge RR, Gage BF, Teagarden JR. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010; 55: 2804-12.
10. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, Robinson M, Barton S, Brunisholz K, Mower CP, Huntinghouse JA, Rollo JS, Siler D, Bair TL, Knight S, Muhlestein JB, Carlquist JF. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 2012; 125: 1997-2005.
11. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SFS, May HT, Samuelson KM, Muhlestein JB, Carlquist JF; Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116: 2563-70.
12. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008; 83: 460-70.
13. Burmester JK, Berg RL, Yale SH, Rottscheit CM, Glurich IE, Schmelzer JR, Caldwell MD. A randomized controlled trial of genotype-based Coumadin initiation. Genet Med 2011; 13: 509-18.
14. Wang M, Lang X, Cui S, Fei K, Zou L, Cao J, Wang L, Zhang S, Wu X, Wang Y, Ji Q. Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial. Int J Med Sci 2012; 9: 472-9.
15. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER III, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA III, Gujral J, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013; 369: 2283-93.
16. Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJ, Redekop WK, Remkes M, Rosendaal FR, van Schie RM, Tavridou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 2013;369:2304-12.
17. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013;369:2294-303.
18. Schelleman H, Chen J, Chen Z, Christie J, Newcomb CW, Brensinger CM, Price M, Whitehead AS, Kealey C, Thorn CF, Samaha FF, Kimmel SE. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther 2008; 84: 332-9.
19. Do EJ, Lenzini P, Eby CS, Bass AR, McMillin GA, Stevens SM, Woller SC, Pendleton RC, Anderson JL, Proctor P, Nunley RM, Davila-Roman V, Gage BF. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J 2012; 12: 417-24.